Modifying risks of secondary leukemias: Is drug scheduling important?

Journal of the National Cancer Institute

Volumn 88, Issue 24, 1996, Pages 1787-1788

  Karp, J E ^a   Smith, M A ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; COVALENT BOND; DNA CLEAVAGE; DNA CONFORMATION; DNA DAMAGE; EDITORIAL; LEUKEMIA; LEUKEMOGENESIS; METASTASIS; MUTAGENICITY; RISK MANAGEMENT;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 0030447546     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.24.1787     Document Type: Editorial

References (0)